Structure-Based Drug Design SBDD

SBDD then guided design of a picomolar p38 kinase inhibitor based on binding to this site, BIRB 796 (5). 

---

Also in the 1980s, structure-based drug design (SBDD) underwent a similar cycle. Early proponents oversold what could be achieved through SBDD, thereby causing pharmaceutical companies to reconsider their investments when they discovered that SBDD too was no panacea for filling the drug discovery cornucopia with choice molecules for development. Nevertheless, SBDD was an important advance. 

The iterative structure-based drug design (SBDD) cycle (lead optimization)... 

A SBDD design should be confirmed by a later X-ray complex structure which in turn serves to initiate a cycle of iterative structural-based drug design (SBDD). SBDD starts from X-ray or NMR complex structure of ligand with protein and a design, if synthesized, validated, and confirmed by X-ray, creates a starting point for a new level of SBDD efforts. 

Reich, S.H. and Webber, S.E. (1993) Structure-based drug design (SBDD) every structure tells a story. Perspect. Drug Dis. Design 1 371-390. 

A second way of reducing plasma protein binding makes use of structure-based drug design (SBDD). In a project designed to produce antagonists of the Bcl-2 family of proteins for anticancer use, researchers at Abbott obtained a lead compound for which in vitro potency... 

---